___

• P'ng S, Carnley B, Baker R, Kontorinis N, Cheng W. Undiagnosed myeloproliferative disease in cases of intra-abdominal thrombosis: the utility of the JAK2 617F mutation. Clin Gastroenterol Hepatol. 2008;6(4):472-5.
• Deepak A, Punamiya S, Patel N, Parekh S, Mehta S, Shah N. Prevalence of JAK29V617F) mutation in intra- abdominal venous thrombosis. Trop Gastroenterol. 2011;32(4):279-84.
• Bourke MG, Martin ST, O'Dwyer M, Hanaghan J, Bennani F, Barry MK. Mesenteric venous thrombosis secondary to an unsuspected JAK2 V617F-positive myeloproliferative disorder. Ir J Med Sci. 2012;181(2):285-7.
• Barbui T. How to manage thrombosis in myeloprolif- erative neoplasms. Curr Opin Oncol. 2011;23(6):654- 8.
• Pemmaraju N, Hamilton JP, Cameron AM, Sisson S, Moliterno AR. Abdominal venous thrombosis present- ing in myeloproliferative neoplasm with JAK2 V617F mutation: a case report. J Med Case Reports. 2012;6(1):102.
• Reilly JT, McMullin MF, Beer PA, Butt N, Conneally E, Duncombe A, Green AR, Michaeel NG, Gilleece MH, Hall GW, Knapper S, Mead A, Mesa RA, Sekhar M, Wilkins B, Harrison CN; Writing group: British Com- mittee for Standards in Haematology. Guideline for the diagnosis and management of myelofibrosis. Br J Haematol. 2012;158(4):453-71.